443 related articles for article (PubMed ID: 16550730)
1. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
2. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
3. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
4. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
5. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health.
Goldstein SR
Int J Fertil Womens Med; 1999; 44(5):221-6. PubMed ID: 10569450
[TBL] [Abstract][Full Text] [Related]
6. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
7. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
8. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Hart W; Netelenbos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
Simoncini T; Mannella P; Genazzani AR
Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
[TBL] [Abstract][Full Text] [Related]
10. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
11. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
12. [Clinical experience with raloxifene].
Szúcs J; Pávó I; Jurida N
Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
[TBL] [Abstract][Full Text] [Related]
13. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
14. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
16. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
17. [Selective estrogen receptor modulators (SERMs)].
Matsumoto T
Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
[TBL] [Abstract][Full Text] [Related]
18. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.
Johnell O; Cauley JA; Kulkarni PM; Wong M; Stock JL
J Fam Pract; 2004 Oct; 53(10):789-96. PubMed ID: 15469774
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene for the treatment and prevention of breast cancer?
Pappas SG; Jordan VC
Expert Rev Anticancer Ther; 2001 Oct; 1(3):334-40. PubMed ID: 12113100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
